KAER Biotherapeutics has received a $291,000 Phase 1 Small Business Innovation Research (SBIR) grant from the National Heart Lung and Blood Institute of the National Institutes of Health for “Aerosol delivery of Surfactant for ARDS,” the company said. The grant will fund a study of surfactant aerosolization and delivery for the treatment of acute respiratory distress syndrome using KAER’s SUPRAER aerosol generation technology.
KAER CEO Donovan Yeates commented, “This important new technological innovation will also be applicable to treat other diseases of the lungs that require drugs whose efficacy depends on high doses being delivered in a short time. Short treatment times lead to better patient adherence, efficacy and improved heath care.”
Read the KAER Biotherapeutics announcement.
